This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Longterm Safety and Performance of the JenaValve (JUPITER)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
JenaValve Technology GmbH Identifier:
First received: May 11, 2012
Last updated: July 6, 2017
Last verified: July 2017
The purpose of this registry is to observe longterm performance and safety of the JenaValve TAVI system, in routine medical and everyday conditions.

Condition Intervention
Aortic Stenosis Aortic Insufficiency Device: Transcatheter aortic valve replacement

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: "The JenaValve" EvalUation of Long Term Performance and Safety In PaTients With SEvere AoRtic Stenosis

Resource links provided by NLM:

Further study details as provided by JenaValve Technology GmbH:

Primary Outcome Measures:
  • all-cause mortality [ Time Frame: 30 day ]
    30-day mortality of procedure is defined as all deaths within 30 days after implantation of the JenaValve prosthesis irrespective of the underlying cause of death.

Secondary Outcome Measures:
  • Safety Endpoints [ Time Frame: peri- and post-operatively and at 3, 6, 12, 24 and 36 months ]
    • All-cause mortality,
    • Cardiovascular mortality,
    • Major stroke,
    • Life-threatening or disabling bleeding,
    • Major bleeding,
    • Acute kidney injury,
    • Myocardial infarction,
    • Major vascular complication,
    • Mechanical coronary obstruction,
    • Prosthetic valve thrombus,
    • Prosthetic valve endocarditis,
    • Conduction disturbance and cardiac arrhythmia,
    • Necessity of permanent pacemaker implantation

  • Device Success [ Time Frame: Index Procedure and Immediate Post-operative ]

    The following parameters will be collected to assess device success:

    1. Successful vascular access, delivery and deployment of the device successful retrieval of the device
    2. Correct position of the device in the proper anatomical location
    3. Intended performance of the prosthetic heart valve:
    4. Only one valve implanted in proper anatomical position

  • Effectiveness [ Time Frame: Prior to discharge, at 3, 6, 12, 24 and 36 months ]

    The following parameters will assess effectiveness:

    • Transvalvular aortic peak pressure gradient
    • Transvalvular aortic mean pressure gradient
    • Effective aortic valve area
    • Paravalvular regurgitation coded according to VARC
    • Transvalvular regurgitation coded according to VARC
    • No clinically significant valve migration/dislocation
    • Absence of mechanical coronary obstruction
    • Functional improvement assessment by NYHA functional classification

  • Quality of Life [ Time Frame: at 12 months ]
    The SF-12v2 Health Survey is an abbreviated version of the SF-36 Health Survey that uses 12 of the SF-36 items to measure functional health and well-being from the patient's point of view. The SF-12v2 is a practical, reliable, and valid measure of physical and mental health.

  • Combined Safety Endpoint [ Time Frame: at 30 days ]

    A combined safety endpoint will be assessed at 30 days consisting of the following variables:

    • All-cause mortality
    • Major stroke
    • Acute kidney injury (Stage 3)
    • Life-threatening or disabling bleeding
    • Major vascular complication
    • Peri-procedural myocardial infarction
    • Repeat surgical or interventional procedure for valve-related dysfunction

  • Combined Efficacy Endpoint [ Time Frame: at 12 months ]

    A combined efficacy endpoint will be assessed consisting of the following variables:

    • All-cause mortality (after > 30 days)
    • Failure of current therapy for AS, requiring hospitalization for symptoms of valve-related or cardiac decompensation
    • Prosthetic heart valve dysfunction

Enrollment: 210
Study Start Date: May 2012
Estimated Study Completion Date: May 2019
Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
High risk patients with aortic stenosis Device: Transcatheter aortic valve replacement
Transcatheter aortic valve replacement via a transapical access
Other Name: The JenaValve TAVI System
High risk patients with AI Device: Transcatheter aortic valve replacement
Transcatheter aortic valve replacement via a transapical access
Other Name: The JenaValve TAVI System


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with severe aortic stenosis or with severe aortic insufficiency and an increased risk for an open aortic valve replacement surgery

Inclusion Criteria:

  • Patients suitable for TAVI with the JenaValve according to instructions for use

Exclusion Criteria:

  • Patients unsuitable for TAVI with the JenaValve according to instructions for use
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01598844

Herz- und Diabeteszentrum NRW
Bad Oeynhausen, Germany
Herzzentrum Dresden, Universitätsklinik an der Technischen Universität Dresden
Dresden, Germany
University Hospital
Erlangen, Germany
University Heart Centre
Freiburg, Germany
Asklepios Klinik
Hamburg, Germany
Universitäres Herzzentrum Hamburg
Hamburg, Germany
Herzzentrum der Universität
Köln, Germany
Herzzentrum Leipzig - Universitätsklinik
Leipzig, Germany
Deutsches Herzzentrum München
Munich, Germany
Herzzentrum des Städtischen Klinikums München
Munich, Germany
Herz- und Kreislaufzentrum Rotenburg (Fulda)
Rotenburg (Fulda), Germany
Robert Bosch Krankenhaus Stuttgart
Stuttgart, Germany
St. Antonius Ziekenhuis
Nieuwegein, Netherlands
Universitätsspital Basel
Basel, Switzerland
United Kingdom
King's College Hospital
London, United Kingdom
Sponsors and Collaborators
JenaValve Technology GmbH
Principal Investigator: Olaf Wendler, Prof King's College Hospital, London
Principal Investigator: Hendrik Treede, Prof UKE Hamburg
  More Information

Responsible Party: JenaValve Technology GmbH Identifier: NCT01598844     History of Changes
Other Study ID Numbers: JV03PMS
Study First Received: May 11, 2012
Last Updated: July 6, 2017

Additional relevant MeSH terms:
Constriction, Pathologic
Aortic Valve Stenosis
Aortic Valve Insufficiency
Pathological Conditions, Anatomical
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction processed this record on September 25, 2017